Trump Administration’s Prescription Drug “Blueprint” to Tackle High U.S. Prices Will Need More Action Steps

Commonwealth Fund May 17, 2018
Shawn Bishop, Christina Ramsay and Lovisa Gustafsson

Toplines

• What’s missing from the Trump administration’s plan to lower prescription drug prices
• Patients and their physicians need information about a drug’s clinical value along with its price

Last week, President Trump released his anticipated “blueprint” to tackle high prescription drug prices. Titled “American Patients First: A Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs,” the document identifies four challenges: 1) high list prices for prescription drugs, 2) lack of negotiation tools in federal health programs, 3) high and rising out-of-pocket costs for consumers, and 4) lower drug prices in other countries. While more needs to be known about whether prices in foreign countries affect U.S. prices, the plan includes making America’s drug prices, out-of-pocket...

Today's Sponsors

Today's Sponsor